DaVita (DVA) Expected to Announce Quarterly Earnings on Monday

DaVita (NYSE:DVA) is projected to issue its Q4 2025 results after the market closes on Monday, February 2nd. Analysts expect DaVita to post earnings of $3.34 per share and revenue of $3.5061 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, February 2, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.17 by ($0.66). The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted $2.59 earnings per share. On average, analysts expect DaVita to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.

DaVita Trading Up 1.8%

NYSE:DVA opened at $109.21 on Friday. The business’s 50-day moving average is $113.59 and its 200 day moving average is $125.20. DaVita has a 12 month low of $101.00 and a 12 month high of $179.60. The company has a market capitalization of $7.71 billion, a P/E ratio of 11.25, a P/E/G ratio of 0.66 and a beta of 0.99.

Wall Street Analysts Forecast Growth

DVA has been the topic of several research reports. Zacks Research upgraded shares of DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. UBS Group reaffirmed a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Truist Financial reduced their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research note on Monday, January 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $145.60.

Institutional Trading of DaVita

A number of institutional investors have recently made changes to their positions in DVA. Canada Pension Plan Investment Board purchased a new stake in DaVita in the second quarter valued at about $43,000. iSAM Funds UK Ltd purchased a new position in shares of DaVita in the 3rd quarter valued at approximately $46,000. NewEdge Advisors LLC boosted its stake in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares in the last quarter. Advisory Services Network LLC purchased a new stake in DaVita during the 3rd quarter worth approximately $115,000. Finally, BTG Pactual Asset Management US LLC acquired a new position in DaVita during the 3rd quarter valued at approximately $203,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.